Sponsored by the Quebec Network for Research on Aging (RQRV)
Dr. Barzilai is a chaired Professor of Medicine and Genetics and the Director of the Institute for Aging Research at the Albert Einstein College of Medicine, which is currently the biggest Center in the world to study the Biology of Aging. This Institute is the home of the Nathan Shock Center of Excellence in the Biology of Aging and the Glenn center for the Biology of Human Aging. His interests focus on several basic mechanisms in the biology and genetics of aging. He is the recipient of an NIH a Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families with centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research. Dr. Barzilai is in the board of the American Federation for Aging Research, is its co-scientific director, and has served on several NIA study section. He is also a founder of CohBar Inc., a biotech that develops mitochondrial derived peptides as therapy for aging and its diseases. He is co-PI on the R24 Geroscience (Apollo) grant that is an effort to move the field of aging to translation. He is leading the TAME (Targeting/Taming Aging with MEtformin) multi central study. His work has been profiled by major outlets, including the New York Times, the BBC and PBS’ NOVA science now, TEDx talk Science and is the leading feature on the Ron Howard/Jonathan Silberberg/National Geographic film about the Age of Aging.